Abstract:Objective To detect the expression of CD 44V 6, VEGF and nm23-H1 genes and evaluate its clinical significances on ovarian cancerous tissue.Methods Monoclonal antibodies to CD 44V 6,VEGF,nm23-H1 and SABC immunohistochemistry method were used to detect the expression of CD 44V 6,VEGF and nm23-H1 on the tumor cell in 65 cases of human ovarian cancerous tissue,30 benign ovarian tumor and on the normal ovarian tissues.Results 1) The positive expression rates of both CD 44V 6 and VEGF in groups of ovarian cancers, of stages Ⅱ-Ⅳand of the patient’s survival below 5 years were respectively were higher than that in groups of benign tumors and normal ovarian controls,of stage Ⅰand of the patient’s survival above 5 years,P0.05.The expression rate of CD 44V 6 in metastatic lesions were higher than that in the primary tumor,but that of VEGF was not significant between them.2) The positive expression rate of nm23-H1 in groups of stage Ⅱ-Ⅳ,of the metastases and of the patient’s survival below 5 years were respectively lower than that in the groups of stage Ⅰ-Ⅱ,of primary lesions and of the patient’s survival above 5 years,P0.05.The expression rate of nm23-H1 gene in group of ovarian cancers was higher than that of benign tumor or normal controls too.3) No significant difference was abserved between groups of the patient’s age,of histological types of cancers,of pathological grades of the malignancy and sizes of residual focuses of cancer.Conclusions 1) The results in the experiment indicate that as the expression of CD 44 V6 and VEGF is higher in poor differentiated tmuor and when the diseases reach the lase stage,which is concordance with some documents in which CD 44V 6 is an agent promoting growth, infiltration and metastasis of tumor,and VEGF promote tumor’s vessel growth.2) The higher expression of nm23-H1 primary cancer than that on metastatic lesion in late stage also reflect the function of nm23-H1 as metastasis supressor gene. The result of higher expression of nm23-H1 in cancer group than that in benign tumors or normal controls may be considered as a host compensative phenomenon to suppress tumor.

[Study on Mrna Expression of the Human Novel Gene NM23-H1B in Ovarian Tumor].

Study on the Expression of the Human Novel Gene NM23-H1B in Epithelial Ovarian Cancer

Expression of a novel gene nm23-H1B in epithelial ovarian tumors

Expression of Antimetastatic Gene Nm23-H1 in Epithelial Ovarian Cancer

Expression of Nm23 - H1 Mrna in Human Gastric Carcinoma

Expression of Nm23-H_1 Protein in Human Colorectal Carcinoma

Expression of CD44V6,VEGF and nm23-H1 on Ovarian Cancerous Tissue and Its Clinical Significance

Isolation and Characterization of a Novel Human NM23-H1B Gene, a Different Transcript of NM23-H1

EVALUATION OF THE PROGNOSTIC VALUE OF Nm23 GENE EXPRESSION IN BREAST CANCER

NORTHERN BLOT ANALYSIS OF Nm23 GENE EXPRESSION IN HUMAN LUNG CANCER

[Expression of Mrna Isoforms of Vascular Endothelial Growth Factor in Ovarian Carcinoma]

The Transcriptive Expression and Clinical Significance of Nm23h Gene in Human Breast Carcinoma with RT-PCR Method

Study on the Expression of Nm23 and Its Clinical Significance in Lung Neoplasms

[Expression of DNA Methyltransferase 1, 3A and 3B Mrna in the Epithelial Ovarian Carcinoma].

Relationship Between Mrna Expression of Metastasis Suppressor Gene Nm23 and Clinicopathological Features and Prognosis of Non Small Cell Lung Carcinoma

Expression of Nm23 H_1 Mrna in Hepatocellular Carcinoma

Identification of Mir-23A As a Novel Microrna Normalizer for Relative Quantification in Human Uterine Cervical Tissues

Expression of long non-coding RNA NR2F2-AS1 in human epithelial ovarian cancer

STUDY ON EXPRESSION AND CLINICAL SIGNIFICANCE OF Nm23 AND VEGF IN OVARIAN SEROUS ADENOCYSTIC NEOPLASMS

Gene Microarray Analysis of Lncrna and Mrna Expression Profiles in Patients with High‑grade Ovarian Serous Cancer.

Tissue Mir-193b As A Novel Biomarker for Patients with Ovarian Cancer